On September 8, 2022 The MedTech company NeoDynamics reported that received approval for its innovative pulse biopsy system NeoNavia from the US Food and Drug Administration, FDA (Press release, NeoDynamics, SEP 8, 2022, View Source [SID1234619295]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The US breast biopsy market is estimated to reach $830 million by 2025.

"The FDA approval for NeoNavia is a major milestone for NeoDynamics and a stamp of quality for both the product and NeoDynamics as a whole," said Anna Eriksrud, CEO of NeoDynamics. "The US represents the potentially largest market for the product, where we now also can build on the experience gained with the system in Europe. Preparation for the launch is ongoing and we expect to begin introducing the system to clinicians and potential partners within the next few months."

NeoDynamics intends to work with US clinics to further document the product in clinical practice to support its marketing and sales strategy. A similar strategy is successfully being executed on in Europe, demonstrating the benefits of the product while forging relationships with important clinics to facilitate a broad acceptance and uptake of the system.

NeoNavia is an innovative biopsy system that uses a patented pulse technology for controlled and accurate needle insertion, which is based on research at Karolinska Institutet. NeoDynamics’ goal is for the pulse technology to become the new standard for ultrasound-guided breast biopsies. The product has CE approval in Europe, where it is in clinical use.

On September 8, 2022 Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune diseases, reported that the Company will participate in the following investor conferences (Press release, Myeloid Therapeutics, SEP 8, 2022, View Source [SID1234619294]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 20th Annual Global Healthcare Conference, September 12-14th, 2022, in NY
Jefferies Cell & Genetic Medicine Summit, September 29-30th, 2022, in NY

On September 8, 2022 Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, reported that the Company will participate virtually in the following events (Press release, Sitryx, SEP 8, 2022, View Source [SID1234619293]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Biotechnology Private Company Symposium, Sept. 21-22, 2022
Neil Weir, Chief Executive Officer of Sitryx, will present a company overview on September 21st at 9am ET
Company management will conduct virtual one-on-one meetings with investors during the conference

Longwood Healthcare Leaders Fall Webconference, Sept. 22, 2022
Neil Weir, Chief Executive Officer of Sitryx, will participate in a panel discussion titled "Moving from Data to Medicine"
To learn more about the Longwood event, view the agenda, and request an invitation, visit www.longwoodhealthcareleaders.com. To request an invitation or recommend a colleague, please email [email protected].

Needham Private Biotech Company Virtual 1×1 Forum, Oct. 18-19, 2022
Company management will conduct virtual one-on-one meetings with investors during the conference

On September 8, 2022 Tyra Biosciences, Inc. ( Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, reported that management will participate at the following investor conferences (Press release, Tyra Biosciences, SEP 8, 2022, View Source [SID1234619292]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright’s 24th Annual Global Investment Conference

September 12-14th, 2022
A pre-recorded presentation will be available here on September 12th at 7am ET
Cantor Oncology, Hematology & HemeOnc Conference

September 28th, 2022, in NY
Panel discussion titled, "Resistant to Resistance: Approaches to Address Resistance in Oncology", on September 28th at 11:30am ET

On September 8, 2022 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) reported that the company will participate in the H.C. Wainwright Global Investment Conference in New York City on Wednesday, September 14, 2022 (Press release, Vanda Pharmaceuticals, SEP 8, 2022, https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-in-the-hc-wainwright-global-investment-conference-301620904.html [SID1234619291]). A corporate presentation is scheduled for 8:30 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The corporate presentation given at the H.C. Wainwright Global Investment Conference may be accessed live on Vanda’s corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda’s website for a period of approximately 30 days.